[elfsight_social_share_buttons id=”1″]

Another vaccine rollout might be on the horizon as Monday the FDA approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant mothers.

The vaccine, called Abryvso, is the first and only maternal immunization to help protect newborns immediately at birth through six months.

Abryvso is designed to take a “passive immunity” approach, generating antibodies in the mother that are passed on to the baby. But Pfizer’s executive director for clinical research and development, Iona Munjal, admitted that the company doesn’t know if this process will have an effect on longer-term pulmonary conditions such as asthma.

This comes just weeks after the FDA approved another RSV vaccine called Beyfortus, which is meant to be given to infants at birth